A Safety and Efficacy Trial Evaluating the Use of Fondaparinux in Percutaneous Coronary Intervention (PCI)(63133)(WITHDRAWN)

Stopped Drug sold to Sanofi-Aventis who sold it to GSK; OBS no longer owns study and does not have data.

Conditions

• Myocardial Infarction
• Coronary Disease

Interventions

• DRUG: fondaparinux sodium
• DRUG: heparin
• PROCEDURE: percutaneous coronary intervention (PCI)

Sponsor

Schering-Plough